IBBQ
Invesco Nasdaq Biotechnology ETF
IBBQ tracks a modified market-cap-weighted index of US biotechnology and pharmaceutical companies listed on the NASDAQ.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 74.5 M
ASSETS UNDER MGMT
19 bp
EXPENSES
Fund Basics
| Inception date | Jun 11, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| VERTEX PHARMACEUTICALS INC | 7.4 % |
| AMGEN INC | 7.1 % |
| GILEAD SCIENCES INC | 6.8 % |
| REGENERON PHARMACEUTICALS | 5.0 % |
| ALNYLAM PHARMACEUTICALS INC | 2.9 % |
| REVOLUTION MEDICINES, INC. | 2.6 % |
| BIOGEN IDEC INC | 2.3 % |
| MODERNA, INC. | 2.0 % |
| ARGENX SE ADR | 2.0 % |
| ILLUMINA INC | 2.0 % |
Constituent Breakdown
| Number of holdings | 260 |
| Herfindahl-Hirschman Index | 254 |
| Wgt avg mkt cap (mns) | $46,293 |
| Large cap (>$10bn) | 64.8% |
| Mid cap ($2-10bn) | 20.3% |
| Small cap (<$2bn) | 10.1% |
| Developed mkts. | 94.7% |
| Emerging mkts. | 0.6% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 85.9 % |
 |
NETHERLANDS | 2.2 % |
 |
BRITAIN | 2.0 % |
 |
IRELAND | 1.7 % |
 |
GERMANY | 0.8 % |
 |
FRANCE | 0.8 % |
 |
CHINA | 0.6 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 15.0% | 54.6% | 19.8% | 16.9% | 4.7% | -- | -- | 5.0% |
| Dividend Yield | 0.3% | 1.5% | 1.2% | 1.1% | 1.0% | -- | -- | 1.0% |
| Total Returns | 15.3% | 56.1% | 21.0% | 18.0% | 5.7% | -- | -- | 5.9% | Ann. Volatility | 22.5% | 20.1% | 21.4% | 20.0% | 22.0% | -- | -- | 21.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.77 | 23% |
| MSCI EAFE | 0.72 | 31% |
| MSCI Emg Mkts | 0.33 | 14% |
Liquidity Measures
| Avg. volume (000) | 35 |
| ADV traded (mns) | $1 |
| Turnover | 1.5% |
| Avg. Bid/Ask (% of price) | 0.17% |
Technical Indicators
| 30d moving avg. (EMA) | $31.50 |
| Relative strength (RSI) | 62 |
| MACD/Signal | 1.13/0.97 |
| Bollinger Bands (Upper/Lower) | $35.05/$28.41 |
| Short interest (% of AUM) | 7.4% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. IBBQ |
Expenses vs. IBBQ |
ALTAR Score™ vs. IBBQ |
|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 79.9% | +26 bp | -0.8% |
| BBH | VanEck Biotech ETF | 49.3% | +16 bp | +4.5% |
| XBI | State Street SPDR S&P Biotech ETF | 40.6% | +16 bp | -0.4% |
| PBE | Invesco Biotechnology & Genome ETF | 38.1% | +39 bp | +2.6% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 37.6% | +41 bp | +6.8% |
| BBP | Virtus LifeSci Biotech Products ETF | 35.5% | +60 bp | -3.8% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 32.0% | +37 bp | +1.4% |
| BMED | Future Health ETF | 28.7% | +66 bp | +0.8% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 28.3% | +16 bp | -3.8% |
| WDNA | WisdomTree BioRevolution Fund | 27.1% | +26 bp | -2.9% |
Risk and Returns: IBBQ vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/15/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.3%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,400 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. IBBQ's ALTAR Score™ is approximately -2.4 standard
deviations above the category average. This places IBBQ in the 1st percentile
among funds in the category.
Sell-Side Consensus
$36.37
PRICE TARGET
+12.0%
UPSIDE